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Summary The understanding of the pathophysiology and the monitoring of metastatic bone disease remains unsatisfactory. We compared
several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of
the bisphosphonate pamidronate. We studied 19 ambulatory patients-with advanced breast cancer and extensive bone metastases who did
not receive any systemic antineoplastic therapy. Pamidronate was administered at doses of 30, 60, 90 or 120 mg and the patients were
followed weekly during a mean of 8 (range 4-10) weeks. Compared with healthy premenopausal women, the percentage of elevated values
at baseline was 47% for fasting urinary calcium (uCa), 74% for hydroxyproline, 83% for CrossLaps (a new marker of type collagen
degradation) and 100% for the collagen cross-links (measured by high performance liquid chromatography), namely pyridinoline (Pyr) and
deoxyPyr (D-Pyr). Pretreatment levels of uCa did not correlate significantly with any of the four markers of bone matrix resorption, whereas the
correlations between these four markers were generally significant (rs=0.43-0.71). Alkaline phosphatase correlated significantly with markers
of bone matrix resorption (rs=0.54-0.74). All parameters, except phosphaturia (uPi) and the bone formation markers (osteocalcin and alkaline
phosphatase), fell significantly after pamidronate therapy, up to day 42 for hydroxyproline, D-Pyr and CrossLaps and day 56 for uCa. This
longer lasting effect was probably due to the parathyroid hormone (PTH) surge following the decrease in serum calcium, implying that the
decrease in uCa can overestimate the effects of bisphophonates on bone resorption. The decrease in bone turnover parameters was most
marked for CrossLaps, indicating the potential ofthis new marker for monitoring therapy. Sequential determinations of markers of bone matrix
resorption should be useful in delineating the optimal therapeutic schemes of bisphosphonates and for evaluating treatment effects on bone
in cancer patients.
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The monitoring of metastatic bone disease remains a daily chal-
lenge for the practising oncologist. Metastatic tumour cells in the
skeleton markedly stimulate osteoclast-mediated bone resorption,
and biochemical parameters ofbone resorption could be useful for
a sensitive and specific assessment of the extent of tumour-
induced osteolysis (TIO) (Body, 1992). The fasting urinary excre-
tions of calcium (uCa) and of hydroxyproline constitute the
classical and widely available parameters of bone resorption in
cancer patients (Niell et al, 1983; Body et al, 1987; Body, 1992).
In patients receiving systemic treatment for bone metastases
from breast cancer, Coleman et al have shown a decrease in uCa 1
month after systemic therapy in those patients subsequently shown
to be 'partial responders' by classical UICC criteria. The same
patients also had a transient increase in the levels of bone
formation markers (Coleman et al, 1988). Several new markers of
bone turnover have recently been introduced that are claimed to be
more sensitive and more specific for assessing bone turnover than
uCa or hydroxyproline, and the clinician is now faced with an
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impressive choice of markers (Delmas, 1990). The intermolecular
cross-linking compounds of collagen could be particularly well
suited to the diagnosis and monitoring of the breakdown of bone
matrix by cancer cells because of their high specificity for bone,
particularly deoxypyridinoline (Delmas et al, 1991; Uebelhart et
al, 1991); however, their evaluation in cancer patients is still quite
limited (Lipton et al, 1993).
On the other hand, bisphosphonates have become the standard
treatment of tumour-induced hypercalcaemia (TIH) (Body et al,
1987; Body, 1992; Ralston, 1992), and they are increasingly used
for the treatment of bone metastases as the essential pathogenic
role ofosteoclasts in tumour-induced osteolysis (TIO) is now well
demonstrated (Averbuch, 1993; Body, 1993). Optimum thera-
peutic schemes remain, however, largely unknown (Averbuch,
1993; Body, 1993), and the use ofbiochemical parameters ofbone
turnover could be quite useful in the determination of such
schemes. Moreover, biochemical markers could help provide a
better understanding of the pathophysiology of TIO, notably the
possible uncoupling between bone formation and bone resorption
(Body, 1992).
We have compared several markers of bone turnover in 19
patients with breast cancer-induced osteolysis before and after a
single infusion of the bisphosphonate pamidronate to better delin-
eate the relative interest of newly developed markers of bone
resorption compared with the routinely used uCa.
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Figure 1 Individual concentrations of uCa, hydroxyproline, Pyr, D-Pyr and CrossLaps in 19 normocalcaemic patients with breast cancer metastatic to bone.
Values are compared with the upper limit of normal values in premenopausal (----) or post-menopausal ( ) women
METHODS (n=5), 90 mg (n=5) and 120 mg for the last five patients. All
patients were followed weekly during 8 (range 4-10) weeks after
Patients the first infusion.
We studied 19 post-menopausal patients suffering from advanced
breast cancer and extensive metastatic bone involvement who were
no longer eligible for standard antineoplastic treatments. The pres-
ence of bone metastases was demonstrated by scintigraphy and
radiography, and by CT scan when necessary. The extent of bone
metastatic involvement was estimated by counting on radiographs
the number of bones involved; we counted only one site when the
invaded bones were adjacent (e.g. vertebrae). The median number
of invaded skeletal sites was four (range 2-8). We estimated the
influence of the extent of bone metastatic involvement on the
levels of biochemical parameters by separating the patients into
three groups, i.e. patients with 2-3, 4-6 or > 6 invaded bones.
The patients did not receive any other systemic antineoplastic
therapy or any drug known to influence bone or calcium metabo-
lism during the study period. All subjects were ambulatory female
patients suffering from advanced metastatic breast cancer, with a
median age of 60 (range 40-78) years. This study was part of a
trial protocol examining the dose-response effects ofpamidronate
in patients with TIO (Body et al, 1995) that had been approved
by the Ethics Committee of Institut J Bordet. All patients were
normocalcaemic, and they were recruited and treated consecu-
tively by the following doses ofpamidronate (Aredia, Ciba-Geigy,
Basle, Switzerland): 30 mg for the first four patients, then 60 mg
Laboratory determinations
Blood measurements included serum calcium (normal values, Nl
2.12-2.57 mmol 1-'), inorganic phosphate (Pi, Nl 0.71-1.45 mmol
1-'), intact PTH (Incstar assay, Nl 10-50 pg ml-'), alkaline phos-
phatase (Alk Phos, Nl <110 mU ml-') and osteocalcin (BGP,
Incstar assay; Nl 0.8-5.7 ng ml-') (Body et al, 1992 1995; Dumon
and Body, 1995). Because of the pathological increase in bone
resorption afterthe menopause (Delmas, 1990; Delmas et al, 1991;
Uebelhart et al, 1991), parameters of bone resorption were
compared with values measured in pre- as well as in post-
menopausal untreated healthy women. Urinary measurements (2-h
morming-fasting specimens) included uCa (Nl <0.45 or <0.59
mmol per mmol ofcreatinine in pre- and post-menopausal women
respectively), uPi, hydroxyproline (NI <37 or <40 ,umol per mmol
of creatinine), pyridinoline (Pyr, Nl <47 or <78 nmol per mmol
of creatinine) and deoxyPyr (D-Pyr, NI <7.3 or <12.0 nmol per
mmol ofcreatinine) (Delmas, 1990; Delmas et al, 1991; Uebelhart
et al, 1991; Body and Delmas, 1992; Body et al, 1995). Cross-
links were measured by fluorometry after extraction, cellulose
chromatography and high-performance liquid chromatography
(HPLC) (Uebelhart et al, 1990).
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Figure 2 Correlations (non-parametric) between baseline values of D-Pyr and other markers of bone resorption, namely uCa, hydroxyproline, Pyr and
CrossLaps in 19 patients with breast cancer metastatic to bone. Note that the correlations remained significant with hydroxyproline, Pyr and CrossLaps when
the patient with the highest values was not taken into account
We also measured CrossLaps excretion before therapy and at
days 7, 21, 42, 56 and 70 after pamidronate. The CrossLaps assay
(Osteometer, Denmark) estimates the level of type I collagen
degradation using an ELISA based on an eight amino acid peptide
sequence specific to the C-telopeptide a, chain of collagen; this
sequence contains an important region for the intermolecular
cross-links (Bonde et al, 1994) (Nl <408 or <780 ,ug mmol-' crea-
tinin in pre- and post-menopausal women respectively).
Statistical analysis
We used classical statistical tests (non-parametric correlations (rs)
and t-tests) with the Statistica program version 4 (Statsoft, Tulsa,
OK, USA). An analysis of covariance (ANCOVA, with mean
pretreatment determinations as the co-variable) was performed to
compare the changes in the different markers after therapy. We
also used non-parametric confidence intervals to estimate the dura-
tion of the effects ofbisphosphonate therapy.
RESULTS
Baseline values
The mean values ofthe evaluated markers ofbone resorption (uCa,
hydroxyproline, Pyr, D-Pyr, CrossLaps) are shown in Figure 1.
Compared with the upper limit ofnormal values in premenopausal
women, uCa, hydroxyproline, Pyr, D-Pyr and CrossLaps levels
were increased in 9/19 (47%), 14/19 (74%), 19/19 (100%), 19/19
(100%) and 15/18 (83%) patients respectively (p<0.0001 by
chi-square analysis, but the differences were not significant
between uCa, hydroxyproline and CrossLaps). When compared
with the upper limit of normal values in oestrogen-depleted post-
menopausal women, the same values were increased in 5/19
(26%), 13/19 (68%), 17/19 (89%), 15/19 (79%) and 5/18 (28%)
respectively (P<0.0001, but the differences were not significant
between uCa and CrossLaps). Compared with normal post-
menopausal women, the mean values were thus not increased
for uCa and barely for CrossLaps, but they were elevated 1.5-
fold, 1.9-fold and 1.8-fold for hydroxyproline, Pyr and D-Pyr
respectively.
Pretreatment levels of uCa did not correlate significantly with
any of the four markers of bone matrix resorption (rs=0.13-0.41,
NS), whereas the correlations between these four markers were all
statistically significant (rs=0.64-0.71, P<0.001) except between
Pyr and CrossLaps (rs=0.43, P=0.08). The correlations between D-
Pyr and the four other markers of bone resorption are depicted in
Figure 2. None of the markers correlated with the extent of bone
metastatic involvement (see Methods).
Mean (±s.d.) BGP concentrations were 4.1±1.7 ng ml (5/19
elevated values), and alkaline phosphatase levels were 191±266
mU ml-' (10/19 elevated values). Alkaline phosphatase levels
were more often elevated than BGP, 53% compared with 26%, but
this difference was not statistically significant. BGP levels did
correlate with hydroxyproline (rs=0.50, P<0.05) but not signifi-
cantly with the other markers, whereas alkaline phosphatase corre-
lated significantly (P<0.05) with all markers of bone matrix
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Figure 3 Relative changes in markers of bone turnover ai
therapy. Changes in markers of bone resorption, either of
O; Pyr, M; CrossLaps, 0; hydroxyproline, A or of the mine
shown in A whereas changes in markers of bone formatio
BGP, 0) are depicted in B; the changes in D-Pyr are show
comparison
resorption, namely Pyr (rs=0.74), D-Pyr (rs=0.54)
(rs=0.58) and CrossLaps (rs=0.56).
Effects of pamidronate therapy
All parameters of bone resorption, except phospl
significantly (at least P<0.05) after pamidrona
intensity and the duration of the decrease in the c
the evaluated markers was significantly diffe
ANCOVA with baseline values as the covariate
longer different from baseline values at day 6
confidence interval, 35-70+ days), day 49 for
(28-70+ days), day 49 for D-Pyr (21-70+ da;
CrossLaps (21-70+ days) and day 21 for Py
Parameters of bone formation did not change si
relative falls compared to baseline are depicted
reached 13% ofbaseline levels for CrossLaps, 550I
for Pyr, 31% for uCa and 57% for hydroxyproline
decreased slightly, from 9.3±0.1 to 8.8±0.1 mg d
PTH levels increased from 30±4 to 90±14 pg m
remained significantly higher than baseline up to and including
day 28 (not shown).
As for baseline concentrations, correlations between the nadirs
(day 7 or 14) in markers levels after pamidronate therapy were
not significant between uCa and the markers of bone matrix
resorption (rs=0.33-0.39, NS), whereas the correlations between
these markers were all statistically significant between each
other (rs=0.60-0.83, P <0.05). There was no correlation with the
changes in the levels of bone formation markers.
DISCUSSION
Our data indicate that markers of bone matrix resorption are more
frequently elevated and to a higher degree than fasting urinary
60 80 calcium or bone formation markers in patients with breast cancer-
induced osteolysis. This was less the case, however, for CrossLaps
excretion, whose sensitivity was lower, as defined by the
percentage of elevated values compared with oestrogen-depleted
post-menopausal women. This can be explained by the marked
increase in CrossLaps levels after the menopause (Gamero et al,
1994). Nevertheless, it remains to be proven that such new
markers of bone resorption have a higher diagnostic yield for bone
metastases than the classical hydroxyproline assay as in our study,
the sensitivity of the CrossLaps assay was not superior to the one
of hydroxyproline. However, the impressive changes in this newer
marker after therapy with bisphosphonates suggest that it could
be especially useful in the monitoring of treatment effects on
bone turnover. The decrease in CrossLaps excretion 1 week after
pamidronate was indeed quite striking, and it would be worthwhile
to monitor changes in such markers after antineoplastic therapy to
60 80 determine if they can detect the future responders earlier than with
conventional scintigraphic or radiological means. This is espe-
cially worthwhile to investigate that this marker can be easily
fter pamidronate measured, unlike crosslinks excretion whose measurement is
the matrix (D-Pyr, quite sophisticated (Delmas et al, 1991; Uebelhart et al, 1991).
nra(ua, P ), are Hydroxyproline, D-Pyr and CrossLaps all remained significantly
'n again in B for lower than baseline up to day 42. After bisphosphonate therapy,
the urinary excretion of calcium appears to be an unreliable
marker in the monitoring of bone resorption during therapy, as it is
further decreased by the PTH surge following the decrease in
hydroxyproline serum calcium and could thus overestimate the duration of the
effects of bisphosphonates on bone resorption. The superiority of
the markers of bone matrix resorption compared with uCa in the
monitoring of osteolysis should, however, be confirmed in longer
term studies. The absence of significant changes in phosphaturia
haturia (uPi), fell was probably owing to contrasting effects, namely the decrease in
ite therapy. The filtered load, itself due to the inhibition of bone resorption, in
-oncentrations of opposition with the phosphaturic effect of PTH.
rent (P<0.0001, Markers of bone matrix resorption correlated well with each
). They were no other, whether before or after pamidronate administration. We
3 for uCa (90% chose to focus on the correlations with D-Pyr because of the well-
hydroxyproline demonstrated specificity of this marker for assessing resorption of
Lys), day 56 for bone collagen (Delmas, 1990; Delmas et al, 1991). The complete
r (14-28 days). lack of correlation between uCa and the markers of bone matrix
ignificantly. The resorption, whether before or after therapy, also indicates the rela-
in Figure 3 and tive inadequacy of uCa to correctly reflect bone destruction in
Yo for D-Pyr, 77% patients with bone metastases. We found no evident relationship
Serum calcium with the extent of bone metastatic involvement as evaluated by
11-' on day 7, but radiographs, but this should be further analysed in a larger series
1' on day 7 and of patients.
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When evaluating cross-linking amino acids ofcollagen (Pyr and
D-Pyr) in patients with TIH, we observed that these markers of
bone matrix resorption were relatively less increased than uCa and
that they also decreased less after therapy (Body and Delmas,
1992). The meaning of our observations was, however, unclear as
uCa levels are influenced by the filtered load of calcium which is
obviously increased in TIH and by the recovery of PTH secretion
after bisphosphonate therapy (Body et al, 1992). Nevertheless,
Coleman et al have also observed in a series of 20 patients with
breast cancer-induced osteolysis that the decrease in Pyr and D-Pyr
after oral pamidronate therapy was lower than the fall in uCa
(Coleman et al, 1992). These findings could thus suggest a prefer-
ential removal of bone mineral rather than bone matrix during
the process of malignant osteolysis and a similar preferential
inhibitory activity of bisphosphonates (Body and Delmas, 1992;
Coleman et al, 1992). However, the present data do not support
this hypothesis. Urinary calcium was thus less often and less
markedly increased than markers of bone matrix destruction
before therapy. After bisphosphonate, the fall in CrossLaps excre-
tion was also more marked than the fall in uCa despite the fact that
the increase in PTH secretion contributed to the latter. Moreover,
our data also argue against the existence of a marked uncoupling
between bone resorption and bone formation in patients with
tumour-induced osteolysis (Body, 1992). Although more sensitive
markers of bone formation are needed to fully assess this hypoth-
esis, bone resorption was relatively more increased than bone
formation; but the correlations between markers ofbone resorption
and Alkaline Phosphatase levels were all statistically significant.
The fact that these correlations were no longer present and that
there were no significant changes in BGP or alkaline phosphatase
levels after pamidronate therapy suggest that bisphosphonates can
indeed uncouple bone turnover in a favourable direction. Bispho-
sphonates offer great promise for the treatment and the prevention
of bone metastases. Optimal therapeutic schemes remain, how-
ever, to be determined and the sequential measurement of markers
of bone matrix resorption should help in the selection of adequate
therapeutic regimens.
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